Skip to main content
. Author manuscript; available in PMC: 2016 Dec 19.
Published in final edited form as: Mol Pharm. 2015 May 8;12(6):1929–1938. doi: 10.1021/mp5006917

Figure 4.

Figure 4

Biodistribution of 177Lu-DOTA-PEG4-LLP2A (3.6 MBq, 90 ng) in B16F10 tumor-bearing mice at 4, 24, 48, 72, and 96 h postinjection, with or without excess LLP2A-PEG4 as a blocking agent (n = 5).